| P | OR | 95% CL of OR |
---|
Model 1 |
HOMA-IR | 0.039* | 1.563 | 1.023 | 2.388 |
Model 2 |
Age | 0.191 | 0.972 | 0.931 | 1.014 |
Gender | 0.356 | 1.400 | 0.686 | 2.857 |
Duration of DM | 0.781 | 1.008 | 0.954 | 1.065 |
Duration of HBP | 0.300 | 0.973 | 0.925 | 1.024 |
HOMA-IR | 0.019* | 1.702 | 1.090 | 2.657 |
Model 3 |
Age | 0.318 | 0.978 | 0.936 | 1.022 |
Gender | 0.356 | 1.401 | 0.685 | 2.866 |
Duration of DM | 0.931 | 1.003 | 0.947 | 1.061 |
Duration of HBP | 0.352 | 0.976 | 0.927 | 1.027 |
HbA1c | 0.304 | 1.114 | 0.907 | 1.369 |
HOMA-IR | 0.037* | 1.623 | 1.029 | 2.560 |
- Notes: Model 1 showed that HOMA-IR is the risk factor for MCI in patients with T2DM; Model 2 showed that HOMA-IR is the risk factor for MCI in patients with T2DM adjusting for age, gender, duration of DM and hypertension; Model 3 showed that HOMA-IR is the risk factor for MCI in patients with T2DM adjusting for age, gender, duration of DM and hypertension as well as HbA1c. * P < 0.05; ** P < 0.01. Abbreviations: MCI, mild cognitive impairment; T2DM, type 2 diabetes mellitus; DM, diabetes mellitus; HBP, high blood pressures; HbA1c, glycosylated hemoglobin